Healthcare Industry News: veterinary
News Release - April 11, 2007
Biophage Pharma appoints new Chief Financial Officer
MONTREAL, April 11 (Healthcare Sales & Marketing Network) - Biophage Pharma Inc. (TSX.V: BUG) a biotechnology company focused on the development of innovative phage-based products for the diagnosis, prevention and control of bacteria contaminations, is pleased to announce the appointment of Mr. Louis Guindon as Chief Financial Officer and Treasurer of the Corporation.With more than 12 years of experience in Corporate Financing, Mergers and Acquisitions, Investor relations and Corporate Development Initiatives, Mr. Guindon will be a big asset to Biophage in its current period of active growth. Louis replaces the corporation's interim CFO, Mr. Myer Bentob, who will remain an active member of the Board.
Mr. Guindon is the founder of Wildon-LJJ inc. a corporate financial services provider offering financial advisory and analytical support to its clients' senior management. Prior to joining Biophage, Mr. Guindon worked at 20-20 Technologies as V.P. Corporate Development, Desjardins Securities, CIBC World Markets and RBC Capital Markets.
"I am very pleased that Mr. Guindon has accepted to act as Chief Financial Officer and Treasurer of the Corporation. Louis brings a wealth of entrepreneurial business experience to our team and his expertise in corporate governance and corporate financing will be invaluable in the development and commercialization of our products and services," said Dr. Rosemonde Mandeville, President and Chief Executive Officer of Biophage. "We would like to thank Mr. Bentob for his excellent work performed in the past few years and the important changes he has contributed in restructuring our financial services. We also appreciate his continued interest and active involvement as a member of our Board of Directors." continued Dr. Mandeville.
About Biophage Pharma Inc.
Biophage Pharma is a high potential, revenue-driven Canadian biotechnology company focused on the development of innovative phage-based products and technologies for the detection, prevention and control of bacterial infections. Founded in 1995, Biophage operates three divisions: (1) The Biosensors division for the development and commercialization of Biosensors, more particularly a portable PDS96(R) Biosensor which is now in the pre-commercialization stage; (2) The phage therapy division for the prevention and control of bacterial contaminations in the medical, veterinary and environment fields; (3) The Immunotox Labs division, which provides services in Immunogenicity and Immunotoxicity, Beryllium sensitivity testing and MELISA(R) testing for the detection of sensitization to more than 200 different allergens including metals, penicillin, gluten and pollens.
(www.biophagepharma.net; www.immunotoxlabs.net)
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Source: Biophage Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!